Literature DB >> 25310301

Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma.

M J Oksman1, M Itälä-Remes1, M Kauppila1, M Putkonen1, U Salmenniemi1, T Salmi1, K Remes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25310301     DOI： 10.1038/bmt.2014.225

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

1.  Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.

Authors:  I M Ghobrial; A Dispenzieri; K L Bundy; D A Gastineau; S V Rajkumar; T M Therneau; M Q Lacy; T E Witzig; M R Litzow; B R Christensen; S Hayman; C G Pribula; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2003-09       Impact factor: 5.483

2.  Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.

Authors:  I Breitkreutz; H M Lokhorst; M S Raab; B van der Holt; F W Cremer; D Herrmann; A Glasmacher; I G H Schmidt-Wolf; I W Blau; H Martin; H Salwender; A Haenel; P Sonneveld; H Goldschmidt
Journal:  Leukemia       Date:  2007-03-22       Impact factor: 11.528

3.  Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo.

Authors:  Stefania Lymperi; Adel Ersek; Francesca Ferraro; Francesco Dazzi; Nicole J Horwood
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.